Dec 01, 2022 / 01:00PM GMT
Ted Tenthoff - Piper Sandler - MD, Analyst
Good morning. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and our next presenting company, Omega, which are posted at the back of the room and also at the registration desk.
Omega is pioneering the development of a novel class of mRNA encoded medicines called Omega Epigenomic Controllers. What we see is target insulated genomic domains to correct expression of disease-causing genes. Omega is conducting the Phase-1/2 MYCHELANGELO study of OTX-2002 in liver cancer patients and have selected OTX-2101 as its next development candidate for lung cancer. Here from the company is Mahesh Karande, President and CEO; and also Tom McCauley, Chief Scientific Officer. Guys, thanks for being with us.
Mahesh Karande - Omega Therapeutics, Inc. - President & CEO
Ted, Thank you. Thank you very much for having us.
Omega Therapeutics Inc at Piper Sandler Healthcare Conference Transcript
Dec 01, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers